Yang Junbao, Wen Xiaomin, Xu Hengyu, Torres-Chinn Nadia, Speake Cate, Greenbaum Carla J, Nepom Gerald T, Kwok William W
Benaroya Research Institute at Virginia Mason, Seattle, WA 98101; and.
Benaroya Research Institute at Virginia Mason, Seattle, WA 98101; and
J Immunol. 2017 Jul 1;199(1):91-96. doi: 10.4049/jimmunol.1601570. Epub 2017 May 26.
CD38 is an activation marker that is present on recently activated T cells, but absent on resting memory T cells. In this study, we show that CD45ROCD38 β cell Ag-specific CD4 T cells were present at higher frequencies in type 1 diabetes subjects compared with those in healthy subjects. These results imply an ongoing β cell immunity years after onset of diabetes and suggest these activated T cells have an active role in the disease process. The Ag specificities of these activated T cells were determined by a novel CD154 T cell epitope mapping assay. Although each patient usually had a unique set of epitopes recognized by these T cells, two epitopes, DR0401-restricted modified preproinsulin peptide 78-90 and zinc transport 8 266-285, were repeatedly identified in multiple subjects. Identifying these T cells and their specific antigenic epitopes might provide immunotherapeutic targets for personalized therapies.
CD38是一种激活标志物,存在于近期激活的T细胞上,但在静息记忆T细胞上不存在。在本研究中,我们发现,与健康受试者相比,1型糖尿病受试者中CD45ROCD38β细胞抗原特异性CD4 T细胞的频率更高。这些结果意味着糖尿病发病数年之后仍存在持续的β细胞免疫,并提示这些激活的T细胞在疾病进程中发挥积极作用。这些激活的T细胞的抗原特异性通过一种新型的CD154 T细胞表位作图测定法来确定。尽管每位患者通常有一组独特的被这些T细胞识别的表位,但在多个受试者中反复鉴定出两个表位,即DR0401限制性修饰的前胰岛素原肽78 - 90和锌转运体8 266 - 285。鉴定这些T细胞及其特异性抗原表位可能为个性化治疗提供免疫治疗靶点。